In non-small cell lung cancer, anaplastic lymphoma kinase (ALK) gene rearrangements represent key oncogenic drivers, and ALK tyrosine kinase inhibitors such as crizotinib have significantly improved clinical outcomes. This evidence concerns the gene ALK and non-small cell lung carcinoma.